Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)

Preventing Anaphylaxis With Acalabrutinib

NCT05038904 ·Status: COMPLETED ·Phase: PHASE2

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

NCT00309907 ·Status: COMPLETED ·Phase: PHASE2

Berotralstat Treatment in Children With Hereditary Angioedema

NCT05453968 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

NCT02303626 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT05024058 ·Status: TERMINATED ·Phase: PHASE3

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

NCT04070326 ·Status: COMPLETED ·Phase: PHASE3

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

NCT06555328 ·Status: TERMINATED ·Phase: PHASE2

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

NCT04444895 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

NCT01193348 ·Status: COMPLETED ·Phase: PHASE2

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

AT1001 for the Treatment of Long COVID

NCT05747534 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

NCT03437278 ·Status: COMPLETED ·Phase: PHASE2

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04753697 ·Status: COMPLETED ·Phase: PHASE3

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

NCT06730126 ·Status: RECRUITING ·Phase: PHASE2

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

NCT05795153 ·Status: COMPLETED ·Phase: PHASE3

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

NCT04213274 ·Status: WITHDRAWN ·Phase: PHASE2

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

NCT05432388 ·Status: COMPLETED ·Phase: PHASE2

Ilaris® Effects in Schnitzler Syndrome (ILESCH)

NCT01390350 ·Status: COMPLETED ·Phase: PHASE2

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332 ·Status: COMPLETED ·Phase: PHASE2

Study of Mepolizumab Safety Syringe in Asthmatics

NCT03021304 ·Status: COMPLETED ·Phase: PHASE3

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025 ·Status: COMPLETED ·Phase: PHASE2

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients

NCT01213641 ·Status: COMPLETED

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218 ·Status: COMPLETED ·Phase: PHASE2